Skip to main content

Table 3 Correlation between NEI-VFQ-25 composite score change and logMAR BCVA change from baseline

From: Correlation between improvement in visual acuity and QOL after Ranibizumab treatment for age-related macular degeneration patients: QUATRO study

  

Correlation coefficient

P value

3 months (N=98)

Total

− 0.27

0.009

Baseline BCVA below 0.5

−0.33

0.02

Baseline BCVA above 0.6

− 0.27

0.10

12 months (N=69)

Total

−0.31

0.01

Baseline BCVA below 0.5

−0.33

0.048

Baseline BCVA above 0.6

−0.39

0.03

  1. BCVA best-corrected visual acuity, logMAR logarithm of the minimal angle of resolution, NEI-VFQ-25 25-item National Eye Institute Visual Function Questionnaire